Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Hepatitis

  Free Subscription


Articles published in J Hepatol

Retrieve available abstracts of 188 articles:
HTML format



Single Articles


    November 2022
  1. CHOI J
    Reply to: Correspondence on "Impact of HBsAg seroclearance on late recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection".
    J Hepatol. 2022;77:1472-1474.
    PubMed    


  2. YUEN MF, Locarnini S, Lim TH, Strasser SI, et al
    Combination treatments including the small-interfering RNA JNJ-3989 induce rapid and sometimes prolonged viral responses in patients with CHB.
    J Hepatol. 2022;77:1287-1298.
    PubMed     Abstract available


    October 2022
  3. ENGEL B, Jaeckel E, Taubert R
    2022 International Autoimmune Hepatitis Group non-response criteria in autoimmune hepatitis: Quick vs. slow responders.
    J Hepatol. 2022 Oct 12. pii: S0168-8278(22)03138.
    PubMed    


  4. TSAI PC, Kuo HT, Hung CH, Tseng KC, et al
    Metformin reduces hepatocellular carcinoma incidence after successful antiviral therapy in patients with diabetes and chronic hepatitis C in Taiwan.
    J Hepatol. 2022 Oct 5. pii: S0168-8278(22)03129.
    PubMed     Abstract available


  5. AGARWAL K, Lok J, Gane E
    Antisense oligonucleotides (ASOs) in chronic hepatitis B infection: Opportunities and challenging the orthodoxy.
    J Hepatol. 2022;77:906-908.
    PubMed    


  6. LEE SK, Kwon JH, Yoon N, Lee SH, et al
    Immune-mediated liver injury represented as overlap syndrome after SARS-CoV-2 vaccination.
    J Hepatol. 2022;77:1209-1211.
    PubMed    


    September 2022
  7. CARSON JM, Barbieri S, Matthews GV, Dore GJ, et al
    National trends in retreatment of HCV due to reinfection or treatment failure in Australia.
    J Hepatol. 2022 Sep 21. pii: S0168-8278(22)03118.
    PubMed     Abstract available


  8. GILLICH N, Zhang Z, Binder M, Urban S, et al
    Effect of variants in LGP2 on MDA5-mediated activation of interferon response and suppression of hepatitis D virus replication.
    J Hepatol. 2022 Sep 21. pii: S0168-8278(22)03113.
    PubMed     Abstract available


  9. OLTMANNS C, Liu Z, Mischke J, Tauwaldt J, et al
    Reverse Inflammaging: Long-term effects of HCV cure on biological age.
    J Hepatol. 2022 Sep 21. pii: S0168-8278(22)03115.
    PubMed     Abstract available


  10. SUN L, Feng H, Misumi I, Shirasaki T, et al
    Viral protease cleavage of MAVS in genetically modified mice with hepatitis A virus infection.
    J Hepatol. 2022 Sep 21. pii: S0168-8278(22)03120.
    PubMed     Abstract available


  11. MARTIN-NAVARRO L, de Andrea C, Sangro B, Argemi J, et al
    In situ detection of vaccine mRNA in the cytoplasm of hepatocytes during COVID19 vaccine-related hepatitis.
    J Hepatol. 2022 Sep 15. pii: S0168-8278(22)03076.
    PubMed    


  12. PEETERS M, Schenk J, De Somer T, Roskams T, et al
    Viral clade is associated with severity of symptomatic genotype 3 Hepatitis E virus infections in Belgium, 2010-2018.
    J Hepatol. 2022 Sep 5. pii: S0168-8278(22)03064.
    PubMed     Abstract available


  13. YI H, Lin Y, Lu B, Mao Y, et al
    The origin of severe hepatitis of unknown aetiology in children: SARS-CoV-2 or adenovirus?
    J Hepatol. 2022 Sep 3. pii: S0168-8278(22)03063.
    PubMed    


  14. SEMMLER G, Lens S, Meyer EL, Baiges A, et al
    Non-invasive tests for clinically significant portal hypertension after HCV cure.
    J Hepatol. 2022 Sep 2. pii: S0168-8278(22)03056.
    PubMed     Abstract available


  15. CHO Y, Bukong TN, Tornai D, Babuta M, et al
    Neutrophil extracellular traps contribute to liver damage and increase defective low-density neutrophils in alcoholic hepatitis.
    J Hepatol. 2022 Sep 2. pii: S0168-8278(22)03060.
    PubMed     Abstract available


  16. YANG H, Bae SH, Jang JW
    Reply to: 'A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance: considerations'.
    J Hepatol. 2022 Sep 1. pii: S0168-8278(22)03057.
    PubMed    


    August 2022
  17. WANG Q, Zhao H, Deng Y, Zheng H, et al
    Validation of Baveno VII criteria for recompensation in entecavir-treated individuals with hepatitis B-related decompensated cirrhosis.
    J Hepatol. 2022 Aug 26. pii: S0168-8278(22)03019.
    PubMed     Abstract available


  18. DIETZ J, Mullhaupt B, Buggisch P, Graf C, et al
    Long-term persistence of HCV resistance-associated substitutions after DAA treatment failure.
    J Hepatol. 2022 Aug 25. pii: S0168-8278(22)03016.
    PubMed     Abstract available


  19. JI D, Chen Y, Bi J, Shang Q, et al
    Entecavir plus Biejia-Ruangan compound reduces the risk of hepatocellular carcinoma in Chinese patients with chronic hepatitis B.
    J Hepatol. 2022 Aug 16. pii: S0168-8278(22)02982.
    PubMed     Abstract available


  20. SNIJDERS RJALM, Gevers TJG, Heneghan MA, Drenth JPH, et al
    Defining endpoints that guide treatment in autoimmune hepatitis.
    J Hepatol. 2022 Aug 16. pii: S0168-8278(22)02991.
    PubMed    


  21. BRUGGEMANN Y, Klohn M, Todt D
    The pivotal role of CD8+ T cells in hepatitis E virus infection.
    J Hepatol. 2022 Aug 14. pii: S0168-8278(22)02986.
    PubMed    


  22. AGGARWAL A, Montanari NR, Ramirez R, Diehl L, et al
    Reply to: Hepatocyte expression of hepatitis B surface and core antigens across phases of chronic hepatitis B infection.
    J Hepatol. 2022 Aug 14. pii: S0168-8278(22)03000.
    PubMed    


  23. JORGENSEN MH, Cananzi M, Buescher G, Samyn M, et al
    Children with autoimmune liver disease have limited access to age-appropriate drug formulations, results from a European survey.
    J Hepatol. 2022;77:551-553.
    PubMed    


  24. WONG AM, Ding X, Wong AM, Xu M, et al
    Unique molecular characteristics of NAFLD-associated liver cancer accentuate beta-catenin/TNFRSF19-mediated immune evasion.
    J Hepatol. 2022;77:410-423.
    PubMed     Abstract available


    July 2022
  25. LI Y, Xiao X, Miao Q, Ma X, et al
    Rapid response predicts complete biochemical response and histological remission in autoimmune hepatitis.
    J Hepatol. 2022 Jul 20. pii: S0168-8278(22)02945.
    PubMed    


  26. SEMMLER G, Meyer EL, Mandorfer M
    De-novo-HCC risk stratification after HCV-cure: All roads lead to Rome?
    J Hepatol. 2022 Jul 19. pii: S0168-8278(22)02944.
    PubMed    


  27. LIU SY, Yuan C, Tong XM
    Antiviral therapy, HBsAg seroclearance and late recurrence of Hepatitis B-related hepatocellular carcinoma.
    J Hepatol. 2022 Jul 18. pii: S0168-8278(22)02938.
    PubMed    


  28. DANDRI M, Volmari A, Lutgehetmann M
    The hepatitis delta virus and chronic hepatitis D.
    J Hepatol. 2022 Jul 15. pii: S0168-8278(22)00337.
    PubMed    


  29. PAPATHEODORIDIS GV, Lekakis V, Voulgaris T, Lampertico P, et al
    Hepatitis B Virus Reactivation Associated with New Classes of Immunosuppressants and Immunomodulators: A Systematic Review, Meta-analysis, and Expert Opinion.
    J Hepatol. 2022 Jul 15. pii: S0168-8278(22)02935.
    PubMed     Abstract available


  30. BUTI M, Craxi A, Foster GR, Maticic M, et al
    Viral hepatitis Elimination: Towards a hepatitis free world.
    J Hepatol. 2022 Jul 13. pii: S0168-8278(22)02934.
    PubMed    


  31. VAN LEEUWEN LPM, de Jong W, Doornekamp L, van Gorp ECM, et al
    Exotic viral hepatitis; a review on epidemiology, pathogenesis, and treatment.
    J Hepatol. 2022 Jul 8. pii: S0168-8278(22)02930.
    PubMed     Abstract available


  32. DI DATO F, Di Giorgio A, Mandato C, Maggiore G, et al
    Italian children seem to be spared from the mysterious severe acute hepatitis outbreak: a report by SIGENP Acute Hepatitis Group.
    J Hepatol. 2022 Jul 6. pii: S0168-8278(22)02924.
    PubMed    


  33. KARIMI-SARI H, Rezaee-Zavareh MS, Falade-Nwulia O, Lim JK, et al
    Non-responders to sofosbuvir/velpatasvir/voxilaprevir in the treatment of chronic hepatitis C infection.
    J Hepatol. 2022 Jul 4. pii: S0168-8278(22)02922.
    PubMed    


  34. AGARWAL K, Lok J, Carey I, Shivkar Y, et al
    A case of HBV-induced liver failure in the REEF-2 phase II trial: Implications for finite treatment strategies in HBV 'cure'.
    J Hepatol. 2022;77:245-248.
    PubMed     Abstract available


  35. LAI MW, Chang YL, Cheng PJ, Chueh HY, et al
    Absence of chronicity in infants born to immunized mothers with occult HBV infection in Taiwan.
    J Hepatol. 2022;77:63-70.
    PubMed     Abstract available


  36. HUANG D, Wu D, Wang P, Wang Y, et al
    End-of-treatment HBcrAg and HBsAb levels identify durable functional cure after Peg-IFN-based therapy in patients with CHB.
    J Hepatol. 2022;77:42-54.
    PubMed     Abstract available


    June 2022
  37. LAMPERTICO P, Roulot D, Wedemeyer H
    BULEVIRTIDE WITH OR WITHOUT PEGIFNalpha FOR PATIENTS WITH COMPENSATED CHRONIC HEPATITIS DELTA: FROM CLINICAL TRIALS TO REAL LIFE STUDIES.
    J Hepatol. 2022 Jun 22. pii: S0168-8278(22)00373.
    PubMed     Abstract available


  38. HOOGEVEEN RC, Dijkstra S, Bartsch LM, Drescher H, et al
    Hepatitis B virus-specific CD4 T-cell responses differentiate functional cure from chronic surface antigen(+) infection.
    J Hepatol. 2022 Jun 15. pii: S0168-8278(22)00366.
    PubMed     Abstract available


  39. MEDAS R, Liberal R, Cardoso H, Macedo G, et al
    2022 International Autoimmune Hepatitis Group non-response criteria in autoimmune hepatitis: a too early endpoint?
    J Hepatol. 2022 Jun 15. pii: S0168-8278(22)00367.
    PubMed    


  40. YUEN MF, Heo J, Kumada H, Suzuki F, et al
    Phase IIa, randomised, double-blind study of GSK3389404 in patients with chronic hepatitis B on stable nucleos(t)ide therapy.
    J Hepatol. 2022 Jun 14. pii: S0168-8278(22)00351.
    PubMed     Abstract available


  41. LURZ E, Lenz D, Bufler P, Fichtner A, et al
    Letter to the editor - A peditatric hepatologists' perspective.
    J Hepatol. 2022 Jun 14. pii: S0168-8278(22)00363.
    PubMed    


  42. SULKOWSKI MS, Agarwal K, Ma X, Nguyen TT, et al
    Safety and efficacy of vebicorvir administered with entecavir in treatment-naive patients with chronic hepatitis B virus infection.
    J Hepatol. 2022 Jun 10. pii: S0168-8278(22)00348.
    PubMed     Abstract available


  43. TANG Y, Chen Y, Chen HN
    A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance: considerations.
    J Hepatol. 2022 Jun 8. pii: S0168-8278(22)00354.
    PubMed    


  44. SZABO G, Thursz M, Shah VH
    Therapeutic advances in alcohol-associated hepatitis.
    J Hepatol. 2022;76:1279-1290.
    PubMed     Abstract available


  45. WONG GLH, Gane E, Lok ASF
    How to achieve functional cure of HBV: Stopping NUCs, adding interferon or new drug development?
    J Hepatol. 2022;76:1249-1262.
    PubMed     Abstract available


    May 2022
  46. ZHANG Z, Ni Y, Lempp FA, Walter L, et al
    Hepatitis D virus-induced interferon response and administered interferons control cell division-mediated virus spread.
    J Hepatol. 2022 May 27. pii: S0168-8278(22)00338.
    PubMed     Abstract available


  47. KEMMING J, Gundlach S, Panning M, Huzly D, et al
    Mechanisms of CD8+ T cell failure in chronic hepatitis E virus infection.
    J Hepatol. 2022 May 27. pii: S0168-8278(22)00334.
    PubMed     Abstract available


  48. ZENG G, Huang J
    The recent outbreak of acute severe hepatitis in children of unknown origin.
    J Hepatol. 2022 May 26. pii: S0168-8278(22)00332.
    PubMed    


  49. YOO S, Kim JY, Lim YS, Han S, et al
    Impact of HBsAg seroclearance on late recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection.
    J Hepatol. 2022 May 25. pii: S0168-8278(22)00329.
    PubMed     Abstract available


  50. QIAN Z, Hao X, Xia Y, Yu W, et al
    Rat Hepatitis E virus is a potential zoonotic pathogen to humans.
    J Hepatol. 2022 May 25. pii: S0168-8278(22)00327.
    PubMed    


  51. KUSHNER T, Djerboua M, Biondi MJ, Feld JJ, et al
    Influence of hepatitis C viral parameters on pregnancy complications and risk of mother-to-child transmission.
    J Hepatol. 2022 May 25. pii: S0168-8278(22)00331.
    PubMed     Abstract available


  52. CHU CM, Liaw YF
    Hepatocyte expression of hepatitis B surface and core antigens across phases of chronic hepatitis B infection.
    J Hepatol. 2022 May 20. pii: S0168-8278(22)00324.
    PubMed    


  53. MA Z, de Man RA, Kamar N, Pan Q, et al
    Chronic hepatitis E: advancing research and patient care.
    J Hepatol. 2022 May 20. pii: S0168-8278(22)00319.
    PubMed     Abstract available


  54. SEUNG KJ, Franke MF, Hewison C, Huerga H, et al
    Corrigendum to 'High prevalence of hepatitis C infection among multidrug-resistant tuberculosis patients' [J Hepatol 72 (2020) 1028-1029].
    J Hepatol. 2022 May 14. pii: S0168-8278(22)00247.
    PubMed    


  55. YEUNG A, Palmateer NE, Dillon JF, McDonald SA, et al
    Corrigendum to 'Population-level estimates of hepatitis C reinfection post scale-up of direct-acting antivirals among people who inject drugs' [J Hepatol 76 (2022) 549-557].
    J Hepatol. 2022 May 9. pii: S0168-8278(22)00248.
    PubMed    


  56. MUCKE MM, Zeuzem S
    The recent outbreak of acute severe hepatitis in children of unknown origin - what is known so far.
    J Hepatol. 2022 May 6. pii: S0168-8278(22)00271.
    PubMed     Abstract available


  57. SEMMLER G, Mandorfer M
    Substantiating evidence for HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease.
    J Hepatol. 2022 May 5. pii: S0168-8278(22)00267.
    PubMed    


  58. BHAGAT N, Verma N, Singh V
    HCC prediction post SVR in HCV patients: many tools yet limited generalizability!
    J Hepatol. 2022 May 5. pii: S0168-8278(22)00264.
    PubMed    


  59. LEMON SM
    Hepatitis A: Current view of an ancient disease.
    J Hepatol. 2022 May 2. pii: S0168-8278(21)02091.
    PubMed    


  60. SONNEVELD MJ, Chiu SM, Park JY, Brakenhoff SM, et al
    Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels.
    J Hepatol. 2022;76:1042-1050.
    PubMed     Abstract available


    April 2022
  61. BAYLIS SA, O'Flaherty N, Burke L, Hogema B, et al
    Identification of rabbit hepatitis E virus (HEV) and novel HEV clade in Irish blood donors.
    J Hepatol. 2022 Apr 26. pii: S0168-8278(22)00250.
    PubMed    


  62. TIAN F, Feld JJ, Feng Z, Sander B, et al
    Feasibility of hepatitis B elimination in high-income countries with ongoing immigration.
    J Hepatol. 2022 Apr 25. pii: S0168-8278(22)00249.
    PubMed     Abstract available


  63. BOETTLER T, Csernalabics B, Salie H, Luxenburger H, et al
    SARS-CoV-2 vaccination can elicit a CD8 T-cell dominant hepatitis.
    J Hepatol. 2022 Apr 21. pii: S0168-8278(22)00234.
    PubMed     Abstract available


  64. YUEN MF, Agarwal K, Ma X, Nguyen TT, et al
    Efficacy and safety of vebicorvir administered in virologically-suppressed patients with chronic hepatitis B virus infection.
    J Hepatol. 2022 Apr 20. pii: S0168-8278(22)00238.
    PubMed     Abstract available


  65. MAUNG NC, Liew ZHS, Leow WQ, Yeong PSJ, et al
    Severe de novo liver injury after Moderna vaccination - not always autoimmune hepatitis.
    J Hepatol. 2022 Apr 16. pii: S0168-8278(22)00236.
    PubMed    


  66. YANG H, Bae SH, Nam H, Lee HL, et al
    A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance.
    J Hepatol. 2022 Apr 7. pii: S0168-8278(22)00208.
    PubMed     Abstract available


  67. FRASER DA, Wang X, Lund J, Nikolic N, et al
    A structurally engineered fatty acid, icosabutate, suppresses liver inflammation and fibrosis in NASH.
    J Hepatol. 2022;76:800-811.
    PubMed     Abstract available


    March 2022
  68. NAKATSUKA T, Tateishi R, Nakagomi R, Minami T, et al
    Risk stratification of hepatocellular carcinoma after hepatitis C virus eradication in patients with compensated advanced chronic liver disease in Japan.
    J Hepatol. 2022 Mar 11. pii: S0168-8278(22)00138.
    PubMed    


  69. TORGERSEN J, Taddei TH, Lo Re V 3rd
    Reply to: "Is it safe to treat chronic hepatitis C patients with decompensated cirrhosis with PI-based DAA?"
    J Hepatol. 2022 Mar 10. pii: S0168-8278(22)00132.
    PubMed    


  70. RUTHER DF, Weltzsch JP, Schramm C, Sebode M, et al
    Autoimmune hepatitis and COVID-19: No increased risk for AIH after vaccination but reduced care.
    J Hepatol. 2022 Mar 10. pii: S0168-8278(22)00120.
    PubMed    


  71. GEHRING AJ, Mendez P, Richter K, Ertl H, et al
    Immunological Biomarker Discovery in Cure Regimens for Chronic Hepatitis B Virus Infection.
    J Hepatol. 2022 Mar 5. pii: S0168-8278(22)00127.
    PubMed     Abstract available


    February 2022
  72. MONTANARI NR, Ramirez R, Aggarwal A, van Buuren N, et al
    Multi-parametric analysis of human livers reveals variation in intrahepatic inflammation across phases of chronic hepatitis B infection.
    J Hepatol. 2022 Feb 23. pii: S0168-8278(22)00123.
    PubMed     Abstract available


  73. RIVERO-JUAREZ A, Frias M, Perez AB, Pineda JA, et al
    Orthohepevirus C infection as an emerging cause of acute hepatitis in Spain: first report in Europe.
    J Hepatol. 2022 Feb 12. pii: S0168-8278(22)00075.
    PubMed     Abstract available


  74. MUELLER PP, Chen Q, Ayer T, Nemutlu G, et al
    Duration and cost-effectiveness of hepatocellular carcinoma surveillance in hepatitis C patients after viral eradication.
    J Hepatol. 2022 Feb 11. pii: S0168-8278(22)00074.
    PubMed     Abstract available


  75. LESLIE J, Geh D, Elsharkawy AM, Mann DA, et al
    Metabolic dysfunction and cancer in HCV: shared pathways and mutual interactions.
    J Hepatol. 2022 Feb 11. pii: S0168-8278(22)00076.
    PubMed     Abstract available


  76. MONTANO-LOZA AJ, Ronca V, Ebadi M, Hansen BE, et al
    Risk factors and outcomes associated with recurrent autoimmune hepatitis following liver transplantation.
    J Hepatol. 2022 Feb 7. pii: S0168-8278(22)00067.
    PubMed     Abstract available


  77. JACHS M, Scheiner B, Pinter M
    Letter to the editor: Immunotherapy for hepatocellular carcinoma in a patient with hepatitis B virus and hepatitis delta virus coinfection.
    J Hepatol. 2022 Feb 3. pii: S0168-8278(22)00030.
    PubMed    


    January 2022
  78. BEHRENDT P, Friesland M, Wissmann JE, Kinast V, et al
    Hepatitis E virus is highly resistant to alcohol-based disinfectants.
    J Hepatol. 2022 Jan 24. pii: S0168-8278(22)00019.
    PubMed     Abstract available


  79. GALLARD C, Lebsir N, Khursheed H, Reungoat E, et al
    Heparanase is upregulated by HCV and favors its replication.
    J Hepatol. 2022 Jan 24. pii: S0168-8278(22)00021.
    PubMed     Abstract available


  80. WONG YJ, Nguyen MH
    Is it safe to treat chronic hepatitis C patients with decompensated cirrhosis with PI-based DAA?
    J Hepatol. 2022 Jan 21. pii: S0168-8278(22)00008.
    PubMed    


  81. PAPE S, Snijders RJ, Gevers TJ, Chazouilleres O, et al
    Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group.
    J Hepatol. 2022 Jan 20. pii: S0168-8278(22)00012.
    PubMed     Abstract available


  82. SHEKHTMAN L, Cotler SJ, Ploss A, Dahari H, et al
    Mathematical modeling suggests that entry-inhibitor Bulevirtide may interfere with hepatitis D virus clearance from circulation.
    J Hepatol. 2022 Jan 4. pii: S0168-8278(21)02307.
    PubMed    


  83. PIHL AF, Feng S, Offersgaard A, Alzua GP, et al
    Inactivated whole hepatitis C virus vaccine employing a licensed adjuvant elicits cross-genotype neutralizing antibodies in mice.
    J Hepatol. 2022 Jan 3. pii: S0168-8278(21)02303.
    PubMed     Abstract available


    December 2021
  84. BEAUMONT E, Larochette V, Preisser L, Miot C, et al
    IL-26 inhibits hepatitis C virus replication in hepatocytes.
    J Hepatol. 2021 Dec 21. pii: S0168-8278(21)02253.
    PubMed     Abstract available


  85. SEMMLER G, Meyer EL, Kozbial K, Schwabl P, et al
    HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease.
    J Hepatol. 2021 Dec 3. pii: S0168-8278(21)02234.
    PubMed     Abstract available


  86. ZHANG M, Zhang Z, Imamura M, Osawa M, et al
    Infection courses, virological features and IFN-alpha responses of HBV genotypes in cell culture and animal models.
    J Hepatol. 2021;75:1335-1345.
    PubMed     Abstract available


    November 2021
  87. SANDUZZI-ZAMPARELLI M, Marino Z, Lens S, Sapena V, et al
    Liver cancer risk after HCV cure in patients with advanced liver disease without non-characterized nodules.
    J Hepatol. 2021 Nov 29. pii: S0168-8278(21)02228.
    PubMed     Abstract available


  88. DE MARTIN E, Duclos-Vallee JC
    Reply to "validation of the SURFASA score to define steroid responsiveness in patients with acute autoimmune hepatitis".
    J Hepatol. 2021 Nov 10. pii: S0168-8278(21)02167.
    PubMed    


  89. TENG Y, Xu Z, Zhao K, Zhong Y, et al
    Novel function of SART1 in HNF4alpha transcriptional regulation contributes to its antiviral role during HBV infection.
    J Hepatol. 2021;75:1072-1082.
    PubMed     Abstract available


    October 2021
  90. LOGLIO A, Ferenci P, Uceda Renteria SC, Tham CYL, et al
    Safety and effectiveness of up to 3 years' bulevirtide monotherapy in patients with HDV-related cirrhosis.
    J Hepatol. 2021 Oct 23. pii: S0168-8278(21)02119.
    PubMed     Abstract available


  91. YUAN S, Yang Y, Hu R
    The Unfolding Multiomics Landscapes of HBV (Hepatitis B Virus)-Host Interactions.
    J Hepatol. 2021 Oct 11. pii: S0168-8278(21)02101.
    PubMed    


  92. YEUNG A, Palmateer NE, Dillon JF, McDonald SA, et al
    Population-level estimates of hepatitis C reinfection post scale-up of direct-acting antivirals among people who inject drugs.
    J Hepatol. 2021 Oct 8. pii: S0168-8278(21)02103.
    PubMed     Abstract available


  93. TUN GS, Gleeson D, Dube A, Al-Joudeh A, et al
    Immune-mediated hepatitis with the Moderna vaccine, no longer a coincidence but confirmed.
    J Hepatol. 2021 Oct 4. pii: S0168-8278(21)02093.
    PubMed    


  94. KIM HY, Lampertico P, Nam JY, Lee HC, et al
    An artificial intelligence model to predict hepatocellular carcinoma risk in Korean and Caucasian patients with chronic hepatitis B.
    J Hepatol. 2021 Oct 1. pii: S0168-8278(21)02087.
    PubMed     Abstract available


  95. MALLET V, Beeker N, Bouam S, Sogni P, et al
    Prognosis of French COVID-19 patients with chronic liver disease: A national retrospective cohort study for 2020.
    J Hepatol. 2021;75:848-855.
    PubMed     Abstract available


  96. WANG GP, Schnell GL, Kort JJ, Sidhu GS, et al
    Linkage of resistance-associated substitutions in GT1 sofosbuvir + NS5A inhibitor failures treated with glecaprevir/pibrentasvir.
    J Hepatol. 2021;75:820-828.
    PubMed     Abstract available


  97. MEIER MA, Calabrese D, Suslov A, Terracciano LM, et al
    Ubiquitous expression of HBsAg from integrated HBV DNA in patients with low viral load.
    J Hepatol. 2021;75:840-847.
    PubMed     Abstract available


    September 2021
  98. CACOUB P, Comarmond C, Vieira M, Regnier P, et al
    HCV-related lymphoproliferative disorders in the direct-acting antivirals era: from mixed cryoglobulinemia to B-cell lymphoma.
    J Hepatol. 2021 Sep 29. pii: S0168-8278(21)02084.
    PubMed     Abstract available


  99. RAHIM MN, Heneghan MA
    Reply to "The Search for Optimum Thiopurine Metabolite Levels in Autoimmune Hepatitis Continues".
    J Hepatol. 2021 Sep 27. pii: S0168-8278(21)02046.
    PubMed    


  100. D'AMBROSIO R, Degasperi E, Anolli MP, Fanetti I, et al
    Incidence of liver and non-liver-related outcomes in patients with HCV-cirrhosis after SVR.
    J Hepatol. 2021 Sep 27. pii: S0168-8278(21)02043.
    PubMed     Abstract available


  101. CHOI WM, Yip TC, Lim YS, Wong GL, et al
    Methodological Challenges in Meta-Analysis to Assess the Risk of Hepatocellular Carcinoma Across Chronic Hepatitis B Treatments.
    J Hepatol. 2021 Sep 27. pii: S0168-8278(21)02079.
    PubMed     Abstract available


  102. KIM HS, Yu X, Kramer J, Thrift AP, et al
    Comparative performance of risk prediction models for hepatitis B-related hepatocellular carcinoma in the United States.
    J Hepatol. 2021 Sep 23. pii: S0168-8278(21)02039.
    PubMed     Abstract available


  103. MALLET V, Scarano Pereira JP, Martinino A, Roque-Afonso AM, et al
    The rise of the hepatitis E virus.
    J Hepatol. 2021 Sep 16. pii: S0168-8278(21)00303.
    PubMed    


  104. LACKNER C, Stauber RE, Tiniakos D
    Reply to: Prognostic value of histologic parameters in alcoholic hepatitis: a word of caution.
    J Hepatol. 2021 Sep 16. pii: S0168-8278(21)02035.
    PubMed    


  105. GAO Y, You M, Fu J, Tian M, et al
    Intratumoral stem-like CCR4+ regulatory T cells orchestrate the immunosuppressive microenvironment in HCC associated with hepatitis B.
    J Hepatol. 2021 Sep 12. pii: S0168-8278(21)02027.
    PubMed     Abstract available


    August 2021
  106. YE Q, Kam LY, Yeo YH, Dang N, et al
    Substantial gaps in evaluation and treatment of patients with hepatitis B in the US.
    J Hepatol. 2021 Aug 30. pii: S0168-8278(21)02014.
    PubMed     Abstract available


  107. CORDES AK, Goudeva L, Lutgehetmann M, Wenzel JJ, et al
    Risk of transfusion-transmitted hepatitis E virus infection from pool-tested platelets and plasma.
    J Hepatol. 2021 Aug 27. pii: S0168-8278(21)02013.
    PubMed     Abstract available


  108. LIN S, Hall A, Kumar R, Quaglia A, et al
    Validation of the SURFASA score to define steroid responsiveness in patients with acute autoimmune hepatitis.
    J Hepatol. 2021 Aug 25. pii: S0168-8278(21)02008.
    PubMed    


  109. ZHOU T, Fronhoffs F, Dold L, Strassburg CP, et al
    New-Onset Autoimmune Hepatitis following mRNA Covid-19 Vaccination in a 36-year-old woman with Primary Sclerosing Cholangitis - should we be more vigilant?
    J Hepatol. 2021 Aug 24. pii: S0168-8278(21)02000.
    PubMed    


  110. DO CARMO RF, de Souza CDF
    Impact of the COVID-19 pandemic on hepatitis C diagnosis in Brazil: Is the global hepatitis C elimination strategy at risk?
    J Hepatol. 2021 Aug 23. pii: S0168-8278(21)01999.
    PubMed    


  111. FERNANDO B
    Autoimmune Hepatitis Developing After Coronavirus Disease 2019 (COVID-19) Vaccine: One or Even Several Swallows Do Not Make a Summer.
    J Hepatol. 2021 Aug 9. pii: S0168-8278(21)01965.
    PubMed    


  112. XU H, Locarnini S, Wong D, Hammond R, et al
    Role of anti-HBs in functional cure of HBeAg+ chronic hepatitis B patients infected with HBV genotype A.
    J Hepatol. 2021 Aug 6. pii: S0168-8278(21)01959.
    PubMed     Abstract available


    July 2021
  113. MISUMI I, Mitchell JE, Lund MM, Cullen JM, et al
    T cells protect against hepatitis A virus infection and limit infection-induced liver injury.
    J Hepatol. 2021 Jul 28. pii: S0168-8278(21)01949.
    PubMed     Abstract available


  114. DELTENRE P, Marot A
    Prognostic value of histologic parameters in alcoholic hepatitis: a word of caution.
    J Hepatol. 2021 Jul 20. pii: S0168-8278(21)01912.
    PubMed    


  115. BORGIA SM, Shafran SD
    Reply to: "Real-world experience of serial serum levels of GS-331007 in chronic hepatitis C hemodialysis patients during and after sofosbuvir/velpatasvir therapy".
    J Hepatol. 2021 Jul 19. pii: S0168-8278(21)01908.
    PubMed    


  116. KIRCHNER T, Jaeckel E, Falk CS, Eiz-Vesper B, et al
    SARS-CoV-2-specific immunity in immunosuppressed COVID-19 convalescents with autoimmune hepatitis.
    J Hepatol. 2021 Jul 17. pii: S0168-8278(21)01911.
    PubMed    


  117. MONTALDO C, Terri M, Riccioni V, Battistelli C, et al
    Fibrogenic signals persist in DAA-treated HCV patients after sustained virological response.
    J Hepatol. 2021 Jul 13. pii: S0168-8278(21)01901.
    PubMed     Abstract available


  118. LODATO F, Larocca A, D'Errico A, Cennamo V, et al
    AN ANUSUAL CASE OF ACUTE CHOLESTATIC HEPATITIS AFTER m-RNABNT162b2 (COMIRNATY) SARS-CoV-2 VACCINE: COINCIDENCE, AUTOIMMUNITY OR DRUG RELATED LIVER INJURY?
    J Hepatol. 2021 Jul 10. pii: S0168-8278(21)01904.
    PubMed    


  119. MCSHANE C, Kiat C, Rigby J, Crosbie O, et al
    The mRNA COVID-19 vaccine - a rare trigger of Autoimmune Hepatitis?
    J Hepatol. 2021 Jul 7. pii: S0168-8278(21)01896.
    PubMed    


  120. LLEWELLYN HP, Arat S, Gao J, Wen J, et al
    T cells and monocyte-derived myeloid cells mediate immunotherapy-related hepatitis in a mouse model.
    J Hepatol. 2021 Jul 6. pii: S0168-8278(21)01887.
    PubMed     Abstract available


  121. BOLIA R, Srivastava A
    The Search For Optimum Thiopurine Metabolite Levels in Autoimmune Hepatitis Continues....
    J Hepatol. 2021 Jul 6. pii: S0168-8278(21)01890.
    PubMed    


  122. GRANITO A, Muratori P, Muratori L
    Acute-on-chronic liver failure: a complex clinical entity in patients with autoimmune hepatitis.
    J Hepatol. 2021 Jul 3. pii: S0168-8278(21)01884.
    PubMed    


  123. YUAN S, Liao G, Zhang M, Zhu Y, et al
    Translatomic profiling reveals novel self-restricting virus-host interactions during HBV infection.
    J Hepatol. 2021;75:74-85.
    PubMed     Abstract available


    June 2021
  124. PAPATHEODORIDI M, Papatheodoridis G
    New concepts in the finite oral antiviral therapy in HBeAg-negative chronic hepatitis B.
    J Hepatol. 2021 Jun 22. pii: S0168-8278(21)00440.
    PubMed    


  125. CLAYTON-CHUBB D, Schneider D, Freeman E, Kemp W, et al
    Comment to the letter of Bril F et al. "Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccine: Causality or casualty?"
    J Hepatol. 2021 Jun 22. pii: S0168-8278(21)00427.
    PubMed    


  126. QUITT O, Luo S, Meyer M, Xie Z, et al
    T-cell engager antibodies enable T cells to control HBV infection and to target HBsAg-positive hepatoma in mice.
    J Hepatol. 2021 Jun 22. pii: S0168-8278(21)00443.
    PubMed     Abstract available


  127. ARAB JP, Diaz LA, Baeza N, Idalsoaga F, et al
    IDENTIFICATION OF OPTIMAL THERAPEUTIC WINDOW FOR STEROID USE IN SEVERE ALCOHOL-ASSOCIATED HEPATITIS: A WORLDWIDE STUDY.
    J Hepatol. 2021 Jun 21. pii: S0168-8278(21)00439.
    PubMed     Abstract available


  128. TAN CK, Wong YJ, Wang LM, Ang TL, et al
    Autoimmune hepatitis following COVID-19 Vaccination: true causality or mere association?
    J Hepatol. 2021 Jun 18. pii: S0168-8278(21)00424.
    PubMed    


  129. BRIL F, Fettig DM
    Response to letter to the editor by Capecchi et al. "Comment to the letter of Bril F et al. "Autoimmune Hepatitis Developing After Coronavirus Disease 2019 (COVID-19) Vaccine: Causality or Casualty?"
    J Hepatol. 2021 Jun 16. pii: S0168-8278(21)00423.
    PubMed    


  130. BOU SALEH M, Louvet A, Ntandja-Wandji LC, Boleslawski E, et al
    Loss of hepatocyte identity following aberrant YAP activation: a key mechanism in alcoholic hepatitis.
    J Hepatol. 2021 Jun 12. pii: S0168-8278(21)00416.
    PubMed     Abstract available


  131. LONDONO MC, Gratacos-Gines J, Saez-Penataro J
    Another case of autoimmune hepatitis after SARS-CoV-2 vaccination. Still casualty?
    J Hepatol. 2021 Jun 12. pii: S0168-8278(21)00417.
    PubMed    


  132. MARCOS-FOSCH C, Cabezas J, Crespo J, Buti M, et al
    Anti-epileptic drugs and hepatitis C therapy: real world experience.
    J Hepatol. 2021 Jun 11. pii: S0168-8278(21)00414.
    PubMed    


  133. ROCCO A, Sgamato C, Compare D, Nardone G, et al
    Autoimmune hepatitis following sars-cov-2 VACCINE: MAY not be a casualty.
    J Hepatol. 2021 Jun 8. pii: S0168-8278(21)00412.
    PubMed    


  134. JANJUA NZ, Wong S, Abdia Y, Jeong D, et al
    Impact of direct-acting antivirals for HCV on mortality in a large population-based cohort study.
    J Hepatol. 2021 Jun 4. pii: S0168-8278(21)00401.
    PubMed     Abstract available


  135. LI J, Liang X, You S, Feng T, et al
    Development and validation of a new prognostic score for hepatitis B virus-related acute-on-chronic liver failure.
    J Hepatol. 2021 Jun 3. pii: S0168-8278(21)00399.
    PubMed     Abstract available


  136. DING ZY, Li GX, Chen L, Shu C, et al
    Association of liver abnormalities with in-hospital mortality in patients with COVID-19.
    J Hepatol. 2021;74:1295-1302.
    PubMed     Abstract available


  137. SARRAZIN C
    Treatment failure with DAA therapy: Importance of resistance.
    J Hepatol. 2021;74:1472-1482.
    PubMed     Abstract available


  138. CHEN J, Liu B, Tang X, Zheng X, et al
    Role of core protein mutations in the development of occult HBV infection.
    J Hepatol. 2021;74:1303-1314.
    PubMed     Abstract available


    May 2021
  139. MATHURIN P
    Early liver transplantation for acute alcoholic hepatitis: we can't say no.
    J Hepatol. 2021 May 28. pii: S0168-8278(21)00354.
    PubMed     Abstract available


  140. KOLAMUNNAGE-DONA R, Berhane S, Potts H, Williams EH, et al
    Sorafenib is associated with a reduced rate of tumour growth and liver function deterioration in HCV-induced hepatocellular carcinoma.
    J Hepatol. 2021 May 27. pii: S0168-8278(21)00350.
    PubMed     Abstract available


  141. HUANG CF, Wei YJ, Wu YT, Chiu YW, et al
    Real world experience of serial serum levels of GS-331007 in chronic hepatitis C hemodialysis patients during and after sofosbuvir/velpatasvir therapy.
    J Hepatol. 2021 May 26. pii: S0168-8278(21)00351.
    PubMed    


  142. MARTINEZ MG, Boyd A, Combe E, Testoni B, et al
    Covalently closed circular DNA: the ultimate therapeutic target for curing Hepatitis B virus infections.
    J Hepatol. 2021 May 26. pii: S0168-8278(21)00348.
    PubMed     Abstract available


  143. DE MARTIN E, Duclos-Vallee JC
    Reply to "Acute severe autoimmune hepatitis - timing for steroids and role of other immunosuppressive agents".
    J Hepatol. 2021 May 26. pii: S0168-8278(21)00345.
    PubMed    


  144. MATTHEWS GV, Bhagani S, Van der Valk M, Rockstroh J, et al
    Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection.
    J Hepatol. 2021 May 20. pii: S0168-8278(21)00336.
    PubMed     Abstract available


  145. RODRIGUES PM, Olaizola P, Banales JM
    Unscrambling a novel pathogenic role for interleukin-20 in acute hepatitis and bacterial infection: A double-edged sword?
    J Hepatol. 2021 May 10. pii: S0168-8278(21)00183.
    PubMed    


  146. SHAH R, Ahovegbe L, Niebel M, Shepherd J, et al
    Non-epidemic HCV genotypes in low- and middle-income countries and the risk of resistance to current direct-acting antiviral regimens.
    J Hepatol. 2021 May 8. pii: S0168-8278(21)00310.
    PubMed     Abstract available


  147. CRESPO J, Diaz-Gonzalez A, Cabezas J
    HCV detection is possible during SARS CoV-2 testing; and throughout COVID-19 vaccination?
    J Hepatol. 2021 May 7. pii: S0168-8278(21)00308.
    PubMed    


  148. CAPECCHI PL, Lazzerini PE, Brillanti S
    Comment to the letter of Bril F et al. "Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) Vaccine: Causality or casualty?"
    J Hepatol. 2021 May 5. pii: S0168-8278(21)00304.
    PubMed    


  149. ZENG DY, Li JM, Lin S, Dong X, et al
    Global burden of acute viral hepatitis and its association with socioeconomic development status, 1990-2019.
    J Hepatol. 2021 May 4. pii: S0168-8278(21)00300.
    PubMed     Abstract available


  150. BREMER W, Blasczyk H, Yin X, Duron ES, et al
    Resolution of hepatitis E virus infection in CD8+ T cell depleted rhesus macaques.
    J Hepatol. 2021 May 4. pii: S0168-8278(21)00301.
    PubMed     Abstract available


  151. REIG M, Cabibbo G
    Antiviral therapy in the palliative setting of HCC (BCLC-B and -C).
    J Hepatol. 2021;74:1225-1233.
    PubMed     Abstract available


  152. HIGASHI-KUWATA N, Hayashi S, Kumamoto H, Ogata-Aoki H, et al
    Identification of a novel long-acting 4'-modified nucleoside reverse transcriptase inhibitor against HBV.
    J Hepatol. 2021;74:1075-1086.
    PubMed     Abstract available


  153. PAPATHEODORIDI M, Hiriart JB, Lupsor-Platon M, Bronte F, et al
    Refining the Baveno VI elastography criteria for the definition of compensated advanced chronic liver disease.
    J Hepatol. 2021;74:1109-1116.
    PubMed     Abstract available


    April 2021
  154. LIBERAL R, Macedo G
    Acute severe autoimmune hepatitis - timing for steroids and role of other immunosuppressive agents.
    J Hepatol. 2021 Apr 29. pii: S0168-8278(21)00297.
    PubMed    


  155. DIETZ J, Sarrazin C
    Reply to "glecaprevir/pibrentasvir + sofosbuvir + ribavirin offers high cure rate for hepatitis C virus retreatment in real-world settings".
    J Hepatol. 2021 Apr 20. pii: S0168-8278(21)00252.
    PubMed    


  156. LLAMOSAS-FALCON L, Shield KD, Gelovany M, Hasan OSM, et al
    Impact of alcohol on the progression of HCV-related liver disease: A systematic review and meta-analysis.
    J Hepatol. 2021 Apr 20. pii: S0168-8278(21)00253.
    PubMed     Abstract available


  157. SONNEVELD MJ, Veldhuijzen IK, van de Laar T, Op de Coul ELM, et al
    DECREASE IN VIRAL HEPATITIS DIAGNOSES DURING THE COVID-19 PANDEMIC IN THE NETHERLANDS.
    J Hepatol. 2021 Apr 19. pii: S0168-8278(21)00250.
    PubMed    


  158. CANDELS LS, Rahim MN, Shah S, Heneghan MA, et al
    Towards personalised medicine in autoimmune hepatitis: Measurement of thiopurine metabolites results in higher biochemical response rates compared to standard weight-based dosing of thiopurine therapy.
    J Hepatol. 2021 Apr 16. pii: S0168-8278(21)00227.
    PubMed     Abstract available


  159. BRIL F, Al Diffalha S, Dean M, Fettig DM, et al
    Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) Vaccine: Causality or casualty?
    J Hepatol. 2021 Apr 13. pii: S0168-8278(21)00237.
    PubMed    


  160. WANG W, Lempp FA, Schlund F, Walter L, et al
    Assembly and infection efficacy of hepatitis B virus surface protein exchanges in eight hepatitis D virus genotype isolates.
    J Hepatol. 2021 Apr 9. pii: S0168-8278(21)00229.
    PubMed     Abstract available


  161. GERLICH W
    Hepatitis B virus - an anaerobic organism?
    J Hepatol. 2021 Apr 2. pii: S0168-8278(21)00166.
    PubMed    


  162. DIETZ J, Di Maio VC, de Salazar A, Merino D, et al
    Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy.
    J Hepatol. 2021;74:801-810.
    PubMed     Abstract available


    March 2021
  163. LIAO SH, Chen CL, Hsu CY, Chien KL, et al
    Long-term Effectiveness of Population-wide Multifaceted Interventions for Hepatocellular Carcinoma in Taiwan.
    J Hepatol. 2021 Mar 6. pii: S0168-8278(21)00163.
    PubMed     Abstract available


  164. CHENG ST, Hu JL, Ren JH, Yu HB, et al
    Dicoumarol, an NQO1 inhibitor, blocks cccDNA transcription by promoting degradation of HBx.
    J Hepatol. 2021;74:522-534.
    PubMed     Abstract available


    February 2021
  165. LIEBE R, Esposito I, Bock HH, Dahl SV, et al
    Diagnosis and management of secondary causes of steatohepatitis.
    J Hepatol. 2021 Feb 9. pii: S0168-8278(21)00096.
    PubMed     Abstract available


  166. IOANNOU GN
    HCC surveillance after SVR in patients with F3/F4 fibrosis.
    J Hepatol. 2021;74:458-465.
    PubMed     Abstract available


    January 2021
  167. SRIDHAR S, Situ J, Cai JP, Yip CC, et al
    Multimodal investigation of rat hepatitis E virus antigenicity: implications for infection, diagnostics, and vaccine efficacy.
    J Hepatol. 2021 Jan 15. pii: S0168-8278(21)00013.
    PubMed     Abstract available


    November 2020
  168. TREBICKA J, Fernandez J, Papp M, Caraceni P, et al
    PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis.
    J Hepatol. 2020 Nov 20. pii: S0168-8278(20)33772.
    PubMed     Abstract available


    October 2020
  169. WANG H, Wen B, Chang X, Wu Q, et al
    Baveno VI criteria and spleen stiffness measurement rule out high-risk varices in virally suppressed HBV-related cirrhosis.
    J Hepatol. 2020 Oct 8. pii: S0168-8278(20)33678.
    PubMed     Abstract available


    March 2020
  170. BUTT AA, Yan P, Shaikh OS, Lo Re V 3rd, et al
    Treatment of HCV reduces viral hepatitis-associated liver-related mortality in patients: An ERCHIVES study.
    J Hepatol. 2020 Mar 4. pii: S0168-8278(20)30120.
    PubMed     Abstract available


    February 2020
  171. HAN JW, Sung PS, Hong SH, Lee H, et al
    IFNL3-adjuvanted HCV DNA vaccine reduces regulatory T-cell frequency and increases virus-specific T-cell responses.
    J Hepatol. 2020 Feb 20. pii: S0168-8278(20)30107.
    PubMed     Abstract available


  172. YEH ML, Huang CF, Huang CI, Holmes JA, et al
    Hepatitis B-related outcomes following direct-acting antiviral therapy in Taiwanese patients with chronic HBV/HCV co-infection.
    J Hepatol. 2020 Feb 13. pii: S0168-8278(20)30074.
    PubMed     Abstract available


  173. LAMPERTICO P, Carrion JA, Curry M, Turnes J, et al
    Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of patients with chronic HCV infection: a meta-analysis.
    J Hepatol. 2020 Feb 12. pii: S0168-8278(20)30072.
    PubMed     Abstract available


  174. VIBERT E, Schwartz M, Olthoff KM
    Advances in resection and transplantation for hepatocellular carcinoma.
    J Hepatol. 2020;72:262-276.
    PubMed     Abstract available


  175. SINGAL AG, Lampertico P, Nahon P
    Epidemiology and surveillance for hepatocellular carcinoma: New trends.
    J Hepatol. 2020;72:250-261.
    PubMed     Abstract available


    January 2020
  176. TSENG TC, Liu CJ, Chang CT, Su TH, et al
    HEV superinfection accelerates disease progression in patients with chronic HBV infection and increases mortality in those with cirrhosis.
    J Hepatol. 2020 Jan 29. pii: S0168-8278(20)30029.
    PubMed     Abstract available


    December 2019
  177. HOORNENBORG E, Coyer L, Boyd A, Alfons Achterbergh RC, et al
    High incidence of HCV in HIV-negative men who have sex with men using pre-exposure prophylaxis.
    J Hepatol. 2019 Dec 17. pii: S0168-8278(19)30719.
    PubMed     Abstract available


  178. AVERHOFF F, Shadaker S, Gamkrelidze A, Kuchuloria T, et al
    Progress and Challenges in a Pioneering Hepatitis C Elimination Program in the Country of Georgia, 2015-2018.
    J Hepatol. 2019 Dec 4. pii: S0168-8278(19)30710.
    PubMed     Abstract available


    November 2019
  179. LIU CH, Lee MH, Lin JW, Liu CJ, et al
    Evolution of eGFR in chronic HCV patients receiving sofosbuvir-based or sofosbuvir-free direct acting antivirals.
    J Hepatol. 2019 Nov 29. pii: S0168-8278(19)30701.
    PubMed     Abstract available


  180. BRASHER NA, Eltahla AA, Underwood A, Boo I, et al
    B cell immunodominance in primary hepatitis C virus infection.
    J Hepatol. 2019 Nov 27. pii: S0168-8278(19)30698.
    PubMed     Abstract available


  181. HAJARIZADEH B, Cunningham EB, Valerio H, Martinello M, et al
    Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: A meta-analysis.
    J Hepatol. 2019 Nov 27. pii: S0168-8278(19)30699.
    PubMed     Abstract available


  182. SHIHA G, Soliman R, Mikhail NN, Easterbrook P, et al
    Educate, Test and Treat Model towards elimination of hepatitis C infection in Egypt: Feasibility and effectiveness in 73 villages.
    J Hepatol. 2019 Nov 14. pii: S0168-8278(19)30672.
    PubMed     Abstract available


  183. HAMMOUTENE A, Biquard L, Lasselin J, Kheloufi M, et al
    A defect in endothelial autophagy occurs in patients with nonalcoholic steatohepatitis and promotes inflammation and fibrosis.
    J Hepatol. 2019 Nov 11. pii: S0168-8278(19)30669.
    PubMed     Abstract available


  184. BROWN RS JR, Buti M, Rodrigues L, Chulanov V, et al
    Glecaprevir/pibrentasvir for 8 weeks in treatment-naive patients with chronic HCV genotypes 1-6 and compensated cirrhosis: the EXPEDITION-8 trial.
    J Hepatol. 2019 Nov 1. pii: S0168-8278(19)30647.
    PubMed     Abstract available


    October 2019
  185. DORE GJ, Feld JJ, Thompson A, Martinello M, et al
    Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial.
    J Hepatol. 2019 Oct 23. pii: S0168-8278(19)30612.
    PubMed     Abstract available


  186. PONS M, Rodriguez-Tajes S, Esteban JI, Marino Z, et al
    Non-invasive prediction of liver related events in HCV compensated advanced chronic liver disease patients after oral antivirals.
    J Hepatol. 2019 Oct 17. pii: S0168-8278(19)30606.
    PubMed     Abstract available


  187. LI Y, Tang L, Guo L, Chen C, et al
    CXCL13-mediated recruitment of intrahepatic CXCR5+CD8+T cells favors viral control in chronic HBV infection.
    J Hepatol. 2019 Oct 11. pii: S0168-8278(19)30602.
    PubMed     Abstract available


    September 2019
  188. CLEMENTS O, Eliahoo J, Un Kim J, Taylor-Robinson SD, et al
    Risk Factors for Intrahepatic and Extrahepatic Cholangiocarcinoma: a systematic review and meta-analysis.
    J Hepatol. 2019 Sep 16. pii: S0168-8278(19)30543.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: